BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx Inc....
BioCentury | Aug 18, 2014
Company News

Horizon Discovery, Otsuka Pharmaceutical deal

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...help to guide development efforts.” Otsuka declined to comment on the deal. Horizon acquired its CombinatoRx...
BioCentury | Jun 9, 2014
Company News

Horizon Discovery Group plc, Zalicus Inc. deal

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...for $8 million. The business will become a subsidiary of Horizon and be named Horizon CombinatoRx Inc....
BioCentury | Jun 2, 2014
Company News

Horizon Discovery, Zalicus deal

...Horizon will acquire Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets for $8...
...$8 million. The business will become a subsidiary of Horizon and will be named Horizon CombinatoRx Inc....
BioCentury | Apr 21, 2014
Company News

Epirus, Zalicus deal

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....
BioCentury | Apr 16, 2014
Top Story

Epirus raises $36 million, to reverse-merge

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
Items per page:
1 - 10 of 249
BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx Inc....
BioCentury | Aug 18, 2014
Company News

Horizon Discovery, Otsuka Pharmaceutical deal

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...help to guide development efforts.” Otsuka declined to comment on the deal. Horizon acquired its CombinatoRx...
BioCentury | Jun 9, 2014
Company News

Horizon Discovery Group plc, Zalicus Inc. deal

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...for $8 million. The business will become a subsidiary of Horizon and be named Horizon CombinatoRx Inc....
BioCentury | Jun 2, 2014
Company News

Horizon Discovery, Zalicus deal

...Horizon will acquire Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets for $8...
...$8 million. The business will become a subsidiary of Horizon and will be named Horizon CombinatoRx Inc....
BioCentury | Apr 21, 2014
Company News

Epirus, Zalicus deal

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....
BioCentury | Apr 16, 2014
Top Story

Epirus raises $36 million, to reverse-merge

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....
Items per page:
1 - 10 of 249